Physician profile
Joseph N Grizzanti
NPI 1932107554
$79,091.65
in general payments reported to CMS, 2019-2025
35 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,708 · 2021: $9,271 · 2022: $5,072 · 2023: $12K · 2024: $6,483 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $10K · Travel and Lodging: $4,259 · Food and Beverage: $3,892 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,805.00 |
| Consulting Fee | $10,345.00 |
| Travel and Lodging | $4,259.42 |
| Food and Beverage | $3,892.25 |
| Education | $149.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63,458.68 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $7,912.93 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Mallinckrodt Hospital Products INC. | $3,100.24 | 2020-2025 | Acthar |
| Csl Behring | $1,047.45 | 2019-2025 | Hizentra, Haegarda |
| Glaxosmithkline, LLC. | $602.20 | 2019-2025 | Nucala |
| Genzyme Corporation | $420.91 | 2019-2025 | |
| Mylan Specialty L.P. | $387.09 | 2019-2024 | Yupelri |
| Pfizer INC. | $254.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.06 | 2020-2025 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $240.50 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $199.63 | 2019-2021 | |
| Insmed, INC. | $124.82 | 2023-2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $115.98 | 2022-2024 | Purified Cortrophin Gel |
| Grifols USA, LLC | $114.84 | 2019-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $112.99 | 2020-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $90.52 | 2019-2023 | Cutaquig |
| Amgen INC. | $85.94 | 2021-2025 | |
| Covis Pharma Gmbh | $83.95 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $52.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.34 | 2022 | |
| Electromed, INC. | $46.59 | 2019-2022 | |
| Genentech USA, INC. | $44.59 | 2019 | |
| Shire North American Group INC | $43.12 | 2019 | |
| Mallinckrodt Enterprises LLC | $41.42 | 2019 | |
| Circassia INC. | $28.35 | 2019 | |
| Alk-Abello, INC | $27.53 | 2019 | |
| United Therapeutics Corporation | $26.21 | 2019 | |
| Optinose US, INC. | $21.66 | 2022 | |
| Philips North America LLC | $20.78 | 2024 | (Ak6) Vest Therapy |
| Viatris Specialty LLC | $18.19 | 2025 | Yupelri |
| Verona Pharma, INC. | $16.99 | 2025 | Ohtuvayre |
| Invivyd INC | $16.63 | 2025 | Pemgarda |
| Biocryst US Sales Co., LLC | $16.15 | 2023 | Orladeyo |
| Azurity Pharmaceuticals, INC. | $15.82 | 2025 | Alvesco |
| Gilead Sciences, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Grizzanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.